/ Media

FDA Approves New Treatment Option for Advanced Melanoma

November 10th, 2015

On November 10, 2015, the FDA approved Cotellic (cobimetinib) for the treatment of people with BRAF V600E or V600K mutation-positive advanced melanoma, for use in combination with Zelboraf (vemurafenib). Cotellic and Zelboraf are not used to treat melanoma with a normal BRAF gene.


News in brief

  • The pivotal coBRIM study showed Cotellic plus Zelboraf reduced the risk of disease worsening or death (progression-free survival; PFS) by about half and helped people live significantly longer (overall survival; OS) compared to Zelboraf alone
  • This FDA approval underscores the important role of targeted medicines to help people with BRAF V600 mutation-positive advanced melanoma

Full Prescribing Information

Patient Information

Read the press release


Supporting Information


Cotellic + Zelboraf Fact Sheet

Understand how the medicines are thought to work.

Skin Cancer: Get the Facts & Know the Risk

Learn about the risk factors and warning signs of skin cancer.

The Changing Face of Skin Cancer

Take a deep dive under the skin and read how we've started to make progress in treating the most common cancer.

Important Safety Information

  • Avoid sunlight during treatment with COTELLIC. COTELLIC can make your skin sensitive to sunlight. You may burn more easily and get severe sunburns. When you go outside, wear clothes that protect your skin, including your head, face, hands, arms, and legs. Use lip balm and a broad-spectrum sunscreen with SPF 30 or higher
  • COTELLIC may cause serious side effects, including risk of new skin cancers, bleeding problems, heart problems, severe rash, eye problems, liver problems, muscle problems (rhabdomyolysis), and skin sensitivity to sunlight (photosensitivity)
  • Tell your doctor if you are pregnant or plan to become pregnant, as COTELLIC can harm your unborn baby. Patients who take COTELLIC should use effective methods of birth control during treatment, and for 2 weeks after the final dose of COTELLIC
  • Do not breastfeed during treatment with COTELLIC and for 2 weeks after the final dose
  • Tell your healthcare provider about all the medicines you take. Certain medicines may affect the blood levels of COTELLIC
  • Common side effects of COTELLIC include diarrhea, sunburn or sun sensitivity, nausea, fever, and vomiting. COTELLIC can also cause changes in blood test results

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of COTELLIC.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see Full COTELLIC Prescribing Information and Patient Information for additional Important Safety Information.

Sandra Horning, M.D.

“When used in combination, Cotellic and Zelboraf help delay disease progression and help people live significantly longer than with Zelboraf alone. With this approval, people with this type of deadly and aggressive skin cancer now have a new targeted option.”